25th Sep 2020 21:22
(Alliance News) - GlaxoSmithKline PLC late Friday said its Nucala medication has received approval in the US to treat Hypereosinophilic Syndrome, a blood disorder.
GSK said Nucala is now the first Food & Drug Administration approved biologic treatment for the disease, which occurs when the blood has a high number of eosinophils, a type of immune cell. A high quantity of eosinophils can overtime damage a body's organs.
"HES is a complex, life-threatening condition that impacts nearly 5,000 patients in the US. Today's approval gives these patients access to a biologic treatment for the first time and demonstrates our commitment to maximising Nucala's impact on eosinophil-driven diseases," GSK's Chief Scientific Officer Hal Barron said.
Glaxo shares closed 1.2% higher at 1,474.40 pence each in London on Friday.
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline